| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Total revenue | ||||||
- | - | 2,646 | - | - | - | |
Total revenue | ||||||
4,896 | 5,991 | - | - | - | 112 | |
Operating expenses: | ||||||
Research and development | ||||||
25,172 | 23,045 | 25,212 | 46,489 | 16,569 | 6,770 | |
General and administrative | ||||||
10,412 | 11,507 | 13,113 | 13,337 | 9,265 | 5,170 | |
Total operating expenses | ||||||
35,584 | 34,552 | 38,325 | 59,826 | 25,834 | 11,940 | |
Operating loss | ||||||
-30,688 | -28,561 | -35,679 | -59,826 | -25,834 | -11,828 | |
Other income, net: | ||||||
Interest income | ||||||
177 | 297 | 87 | - | - | - | |
Interest income | ||||||
- | - | - | - | - | 58 | |
Interest expense | ||||||
2 | 1,047 | 1,048 | - | - | 701 | |
Change in fair value of warrant liability | ||||||
- | - | 0 | - | - | 641 | |
Other income, net | ||||||
136 | 72 | 19 | - | - | 9 | |
Total other income, net | ||||||
311 | -678 | -942 | 127 | 48 | -1,275 | |
Loss from continuing operations | ||||||
- | - | - | -59,699 | -25,786 | -13,103 | |
Loss from discontinued operations | ||||||
- | - | - | - | -2,274 | 1,715 | |
Net Income (Loss) Attributable to Parent | ||||||
-30,377 | -29,239 | -36,621 | -59,699 | -28,060 | -11,388 | |
Comprehensive loss | ||||||
-30,377 | -29,239 | -36,621 | - | - | - | |
Continuing operations | ||||||
- | - | - | -9.97 | -11.36 | -5.95 | |
Discontinued operations | ||||||
- | - | - | - | -1.01 | 0.78 | |
Net loss per share, basic and diluted (in USD per share) | ||||||
-1.16 | -1.13 | -2.29 | -9.97 | -12.37 | -5.17 | |
Weighted-average common shares outstanding, basic and diluted (in shares) | ||||||
26,254 | 25,795 | 15,981 | 5,985 | 2,269 | 2,203 | |
License and collaboration revenue | ||||||
Total revenue | ||||||
4,477 | 5,982 | 2,271 | - | - | - | |
Research and development services revenue | ||||||
Total revenue | ||||||
0 | 9 | 375 | - | - | - | |
Government research contracts and grants revenue | ||||||
Total revenue | ||||||
419 | 0 | - | - | - | - | |